Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
26 04 2021
Historique:
received: 18 11 2020
revised: 18 11 2020
accepted: 24 12 2020
pubmed: 13 1 2021
medline: 9 11 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

Huntington's disease pathogenesis involves a genetic gain-of-function toxicity mechanism triggered by the expanded HTT CAG repeat. Current therapeutic efforts aim to suppress expression of total or mutant huntingtin, though the relationship of huntingtin's normal activities to the gain-of-function mechanism and what the effects of huntingtin-lowering might be are unclear. Here, we have re-investigated a rare family segregating two presumed HTT loss-of-function (LoF) variants associated with the developmental disorder, Lopes-Maciel-Rodan syndrome (LOMARS), using whole-genome sequencing of DNA from cell lines, in conjunction with analysis of mRNA and protein expression. Our findings correct the muddled annotation of these HTT variants, reaffirm they are the genetic cause of the LOMARS phenotype and demonstrate that each variant is a huntingtin hypomorphic mutation. The NM_002111.8: c.4469+1G>A splice donor variant results in aberrant (exon 34) splicing and severely reduced mRNA, whereas, surprisingly, the NM_002111.8: c.8157T>A NP_002102.4: Phe2719Leu missense variant results in abnormally rapid turnover of the Leu2719 huntingtin protein. Thus, although rare and subject to an as yet unknown LoF intolerance at the population level, bona fide HTT LoF variants can be transmitted by normal individuals leading to severe consequences in compound heterozygotes due to huntingtin deficiency.

Identifiants

pubmed: 33432339
pii: 6081928
doi: 10.1093/hmg/ddaa283
pmc: PMC8248964
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-148

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS079651
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS091161
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS105709
Pays : United States
Organisme : NINDS NIH HHS
ID : R03 NS108028
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

Cell. 2015 Jul 30;162(3):516-26
pubmed: 26232222
Hum Mol Genet. 2003 Dec 15;12(24):3359-67
pubmed: 14570710
Cell. 1995 Jun 2;81(5):811-23
pubmed: 7774020
PLoS Genet. 2013 Oct;9(10):e1003930
pubmed: 24204323
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Am J Hum Genet. 2018 Sep 6;103(3):349-357
pubmed: 30122542
Hum Mol Genet. 2019 Feb 15;28(4):650-661
pubmed: 30358836
Orphanet J Rare Dis. 2010 Dec 20;5:40
pubmed: 21171977
Nature. 2018 Mar 1;555(7694):117-120
pubmed: 29466333
Science. 1995 Jul 21;269(5222):407-10
pubmed: 7618107
Hum Mol Genet. 2017 Apr 1;26(7):1258-1267
pubmed: 28165127
Nat Genet. 1995 Oct;11(2):155-63
pubmed: 7550343
Hum Mol Genet. 2009 Aug 15;18(16):3039-47
pubmed: 19465745
Brain. 2019 Jun 19;:
pubmed: 31216018
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70
pubmed: 23341618
Neurology. 2012 Mar 6;78(10):690-5
pubmed: 22323755
Acta Pharmacol Sin. 2016 Sep;37(10):1307-1314
pubmed: 27264314
Nat Genet. 1997 Dec;17(4):404-10
pubmed: 9398841
Structure. 2020 Sep 1;28(9):1035-1050.e8
pubmed: 32668197
PLoS Comput Biol. 2007 Nov;3(11):e235
pubmed: 18039028
Eur J Hum Genet. 2016 Dec;24(12):1833
pubmed: 27834362
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
N Engl J Med. 2019 Jun 13;380(24):2307-2316
pubmed: 31059641
JAMA Neurol. 2020 Jun 1;77(6):764-772
pubmed: 32202594
J Cell Biochem. 2019 Jun;120(6):10519-10529
pubmed: 30672003
PLoS Genet. 2019 Mar 21;15(3):e1007765
pubmed: 30897080
Neuron. 2016 Mar 2;89(5):910-26
pubmed: 26938440
Trends Biochem Sci. 2003 Aug;28(8):425-33
pubmed: 12932731
J Med Genet. 2016 Mar;53(3):190-9
pubmed: 26740508
Neurobiol Dis. 1996;3(3):183-90
pubmed: 8980018
EBioMedicine. 2019 Oct;48:568-580
pubmed: 31607598
Elife. 2016 Mar 22;5:e11184
pubmed: 27003594
Somat Cell Mol Genet. 1994 Jan;20(1):27-38
pubmed: 8197474
Hum Mol Genet. 2010 Feb 15;19(4):573-83
pubmed: 19933700
J Neurosci. 2008 Jun 11;28(24):6182-95
pubmed: 18550760
Cell. 2019 Aug 8;178(4):887-900.e14
pubmed: 31398342
Hum Mol Genet. 2017 Oct 1;26(19):3859-3867
pubmed: 28934397
J Med Genet. 1987 Jul;24(7):410-2
pubmed: 3612716
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Am J Med Genet A. 2009 Jul;149A(7):1375-81
pubmed: 19507258
Neuron. 2012 Jul 12;75(1):41-57
pubmed: 22794259
Neurology. 2019 Apr 30;92(18):e2101-e2108
pubmed: 30867264
Eur J Hum Genet. 2016 Dec;24(12):1826-1827
pubmed: 27329733
Nature. 2017 Apr 12;544(7649):235-239
pubmed: 28406212
J Mol Biol. 2019 Apr 19;431(9):1869-1877
pubmed: 30711541
PLoS One. 2012;7(9):e44273
pubmed: 22970194
Nature. 2020 May;581(7809):459-464
pubmed: 32461653
Brain Pathol. 2016 Nov;26(6):779-786
pubmed: 27529325
Science. 2020 Aug 14;369(6505):787-793
pubmed: 32675289

Auteurs

Roy Jung (R)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Yejin Lee (Y)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Douglas Barker (D)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Kevin Correia (K)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Baehyun Shin (B)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Jacob Loupe (J)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Ryan L Collins (RL)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Medical and Population Genetics Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA.
Program in Bioinformatics and Integrative Genomics, Division of Medical Sciences, Harvard Medical School, Boston, MA 02114, USA.

Diane Lucente (D)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Jayla Ruliera (J)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Tammy Gillis (T)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Jayalakshmi S Mysore (JS)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Lance Rodan (L)

Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
Department of Neurology, Boston Children's Hospital, Harvard Medical School, MA 02115, USA.

Jonathan Picker (J)

Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
Department of Child and Adolescent Psychiatry, Boston Children's Hospital, Harvard Medical School, MA 02115, USA.

Jong-Min Lee (JM)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

David Howland (D)

CHDI Management/CHDI Foundation Inc., Princeton, NJ 08540, USA.

Ramee Lee (R)

CHDI Management/CHDI Foundation Inc., Princeton, NJ 08540, USA.

Seung Kwak (S)

CHDI Management/CHDI Foundation Inc., Princeton, NJ 08540, USA.

Marcy E MacDonald (ME)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.
Medical and Population Genetics Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA.

James F Gusella (JF)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Medical and Population Genetics Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA.
Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, 02115, USA.

Ihn Sik Seong (IS)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH